Literature DB >> 26669789

Ligand-Binding Assay Development: What Do You Want to Measure Versus What You Are Measuring?

Andrew P Mayer1,2, Charles S Hottenstein3,4.   

Abstract

Keywords:  characterize; free/total; immunoassay; ligand-binding assays

Mesh：

Substances：

Year:  2015        PMID： 26669789      PMCID： PMC4779095          DOI： 10.1208/s12248-015-9855-0

Source DB:  PubMed          Journal:  AAPS J        ISSN： 1550-7416            Impact factor:   4.009


× No keyword cloud information.
  14 in total

1.  Pharmacokinetic immunoassay methods in the presence of soluble target.

Authors:  Thorsten Verch; Shannon Chilewski; Silikhone Bouaraphan; Helen Yarovoi; Kuo-Chang Yin; Dave Chen; Michael W Washabaugh
Journal:  J Immunol Methods       Date:  2010-08-07       Impact factor: 2.303

Review 2.  Therapeutic monoclonal antibody concentration monitoring: free or total?

Authors:  Bing Kuang; Lindsay King; Huifen Faye Wang
Journal:  Bioanalysis       Date:  2010-06       Impact factor: 2.681

3.  Development and characterization of a free therapeutic ligand binding assay with assistance from kinetics modeling.

Authors:  LaKenya Williams; Michael Sank; Anjaneya Chimalakonda; Yan Ni; Mark Saewert; Binodh DeSilva; Renuka Pillutla
Journal:  J Immunol Methods       Date:  2015-02-27       Impact factor: 2.303

4.  Specificity and accuracy data for ligand-binding assays for macromolecules should be interpreted with caution.

Authors:  John W A Findlay
Journal:  AAPS J       Date:  2008-07-17       Impact factor: 4.009

5.  Bioanalysis of therapeutic peptides: differentiating between total and anti-drug antibody bound drug using liquid chromatography-tandem mass spectrometry quantitation.

Authors:  Katja Heinig; Thomas Wirz; Eginhard Schick; Alberto Guenzi
Journal:  J Chromatogr A       Date:  2013-09-30       Impact factor: 4.759

6.  Free versus total ligand-binding assays: points to consider in biotherapeutic drug development.

Authors:  Jihong Yang; Valerie Quarmby
Journal:  Bioanalysis       Date:  2011-06       Impact factor: 2.681

Review 7.  Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development.

Authors:  Jean W Lee; Marian Kelley; Lindsay E King; Jihong Yang; Hossein Salimi-Moosavi; Meina T Tang; Jian-Feng Lu; John Kamerud; Ago Ahene; Heather Myler; Cindy Rogers
Journal:  AAPS J       Date:  2011-01-15       Impact factor: 4.009

8.  Specificity of bioanalytical methods for pharmacokinetic support of biological macromolecular therapeutics is important.

Authors:  John W A Findlay
Journal:  Bioanalysis       Date:  2011-03       Impact factor: 2.681

Review 9.  Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation.

Authors:  Marian Kelley; Ago B Ahene; Boris Gorovits; John Kamerud; Lindsay E King; Thomas McIntosh; Jihong Yang
Journal:  AAPS J       Date:  2013-03-30       Impact factor: 4.009

Review 10.  Application and challenges in using LC-MS assays for absolute quantitative analysis of therapeutic proteins in drug discovery.

Authors:  Joanna Zheng; John Mehl; Yongxin Zhu; Baomin Xin; Timothy Olah
Journal:  Bioanalysis       Date:  2014-03       Impact factor: 2.681
View more
  2 in total

1.  Recombinant Anti-idiotypic Antibodies in Ligand Binding Assays for Antibody Drug Development.

Authors:  Stefan Harth; Christian Frisch
Journal:  Methods Mol Biol       Date:  2021

2.  Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics.

Authors:  Stefan Harth; Andre Ten Haaf; Christian Loew; Christian Frisch; Achim Knappik
Journal:  MAbs       Date:  2018-12-05       Impact factor: 5.857
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.